Crohn's disease

News

Disappointment for BMS as Zeposia fails Crohn’s study

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.

News

Stada, Alvotech get first EU approval for biosimilar Stelara

Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protection in July

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phas

News

Sanofi buys into Teva’s anti-TL1A therapy for IBD

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

Disappointment for BMS as Zeposia fails Crohn’s study

Stada, Alvotech get first EU approval for biosimilar Stelara

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

Sanofi buys into Teva’s anti-TL1A therapy for IBD

First Tysabri biosimilar cleared by FDA for MS

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

Crohn's disease

Editor's Picks